- Home
- PEW vs CALC Comparison
PEW vs CALC Comparison
Compare PEW & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PEW | CALC |
|---|---|---|
| Founded | 2007 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 91.5M | 88.3M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | PEW | CALC |
|---|---|---|
| Price | $2.76 | $0.59 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 1 |
| Target Price | ★ $6.75 | N/A |
| AVG Volume (30 Days) | 346.6K | ★ 527.8K |
| Earning Date | 01-01-0001 | 06-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 84.07 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.69 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.55 | $0.46 |
| 52 Week High | $10.04 | $7.20 |
Technical Indicators
Market Signals| Indicator | PEW | CALC |
|---|---|---|
| Relative Strength Index (RSI) | 40.24 | 24.70 |
| Support Level | $2.74 | $0.51 |
| Resistance Level | $3.64 | $0.79 |
| Average True Range (ATR) | 0.13 | 0.07 |
| MACD | 0.01 | 0.16 |
| Stochastic Oscillator | 47.73 | 40.25 |
Price Performance
Historical ComparisonAbout PEW GrabAGun Digital Holdings Inc.
GrabAGun Digital Holdings Inc is a multi-brand eCommerce retailer of firearms, ammunition, and related accessories.
About CALC CalciMedica Inc.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.